In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis.
Since fluoroquinolones have generated much interest because of their excellent in vitro and in vivo activity, their pharmacokinetic propertiesm oral dosing and intracellular penetration, we tested the susceptibility of 146 recent clinical isolated of Brucella melitensis agaist eight 4-quinolone drugs and five conventional drugs. The drugs tested included ciprofloxacin, norfloxacin, temafloxacin, sparfloxacin, fleroxacin, pefloxacin, lomefloxacin, CI-960, tetracycline, gentamicin, streptomycin rifampicin and trimethoprim-sulfamethoxazole. All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug. Lowest MCIs were observed with CI-960 and highest temafloxacin and sparfloxacin. One isolate which had developed resistance to ciprofloxacin while the patient was being treated with this drug exhibited cross-resistance to all the members of the family.